Events
Gilead Sciences announces discovery of orally active influenza inhibitorsGilead Sciences & Hoffman La-Roche announce worldwide influenza collaborationHoffman La-Roche and Gilead Sciences initiate human testing of oral influenza drug GS4104Phase 2 human testing of oral influenza drug GS4104 beginsOral influenza compound reduced symptoms and prevented illness in humansFlu patients in the U.S. may now have access to experimental oral treatments for influenzaGilead announces preliminary results from phase 2/3 studiesGilead announces that partner Hoffmann La-Roche disclosed GS4104 phase 3 study resultsHoffman La-Roche submits NDAFirst FDA approval of Roche's Tamiflu, a new flu treatment
Comments